Does anybody know a method to study the effects of compounds on gap junctions?

In models where in-vivo tests are monitored over days and not hours, a tremendous amount of data is generated. How are other researchers handling these large databases and what tools are used to select the subsets of the total data set for analysis?

Prior to candidate recommendation from discovery, most groups conduct some sort of “ancillary” cardiovascular study. The question is in what model?

Could folks share the in vivo model or models that are typically used (eg. dog, monkey, rat, conscious/anesthetized, etc) to support the advancement of a compound into the toxicology phase of development.  Also, if any models used are established in the company, or outsourced.

Do you have questions or comments about various topics in Safety Pharmacology, but did not know how to get feedback?  Or share ideas with other safety pharmacologists?  What can you do to get a timely answer to your question, or issue?  The new  Safety Pharmacology Society blog (aka SPeak) may be an ideal way to post your question, and get comments from members of the safety pharmacology community.

Have you blogged before?  If not, do not be afraid!  “Blog” is an abbreviation for “web log” or “weblog”, which is a term to describe a website that maintains or chronicles information.  How many safety pharmacology blogs are there?  That is unknown, but SPeak is the official blog established by the Safety Pharmacology Society for the benefit of its members.

So, do you have a question, topic or issue that needs to be discussed?  Consider posting your item (aka content) to this blog, and take advantage of the collective wisdom and experience of the membership.  We could all learn something.

If you have participated in a blog previously, especially a science-based forum, please post a comment and share your experience.

What makes a blog successful?  Good content and participation….so, SPeak UP!!